Eevia Health Plc received small initial sales order for Feno-Sambucus™ from Australia

Eevia Health ("Eevia" or "The Company") received a start order for the Feno-Sambucus™ worth SEK 110 000 from its Australian distributor Ingredient Plus. The order is a new start order for an Australian brand owner.

Eevia Health Plc is a leading health ingredient manufacturer from Finland and is currently the largest manufacturer of elderberry extract in the world. Eevia has received the first order for Feno-Sambucus, an Elderberry extract from Australia. The value of the orders equals a revenue of SEK 12 000.

The end customer is an established player within innovative complementary medicines in Australia, marketing and selling a diversified product range, combining nutrients, herbal and other ingredients. It is a leading supplier of traditional remedies which are available in over 5000 pharmacies and health food stores across Australia. The end customer uses the elderberry ingredients from Eevia in nutraceutical formulations for sales primarily in the Australian market.

Ingredient Plus is a leading and independent Australian distributor of Eevia Health. It has a strong position in Australia also covering other territories in the Asia-Pacific Region across key strategic markets.

CEO Stein Ulve comments: "We are pleased to start export of European Elderberry extracts also to Australia. We have no clear major expectations for a large volume from this customer at this stage, but we all have to start somewhere. This is a welcome start for our Elderberry extract in Australia."

Seinäjoki, Finland 1.12.2022

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          
Email: [email protected]                      
Telephone: +358 400 22 5967                          

This information is such that Eevia Health Plc is required to make it public in accordance with the EU's Market Abuse Regulation (MAR). The information was made public by the Company's contact person above on December 1st, 2022, at 13:40 CET.


Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit or follow Eevia Health on LinkedIn@EeviaHealth. 

Om Eevia Health

Eevia Health targets health problems with bioactive extracts from plant material. The human body has an incredible ability to restore good health. However, sometimes the body needs active support. Our mission is to support good health and well-being with plant extracts which have scientifically documented health benefits. Eevia Health manufactures and markets organic ingredients from abundant plant material in the Arctic. Our products are targeted against low-grade inflammation, problems in eye and brain health, and metabolic effects. We collaborate with scientists in Finland and abroad to scientifically substantiate the positive effects of ingredients and also to document the safety of use.



Kurs ()
Förändring ()
Marknad Spotlight stock market Kortnamn EEVIA ISIN-kod FI4000496658


Stein Ulve IR-kontakt [email protected]